Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

53 results about "Cell Adhesion Inhibition" patented technology

Any cellular process that reduces the frequency, rate or extent of cell adhesion.

Vault agents for chronic kidney disease

The invention relates to compositions of vault complexes containing cell adhesion inhibiting agents, such as a RGD-peptide, and methods of using the vault complexes in the treatment of diseases, such as chronic kidney disease.
Owner:RGT UNIV OF CALIFORNIA

Gel composition for cellular adhesion inhibition

InactiveUS20070031498A1Avoid stickingInhibiting adhesion of cellPowder deliveryBiocideAdhesion processPolyethylene glycol
The invention includes compositions for inhibiting cellular adhesion, methods of preparation of such compositions, and methods for preventing cell adhesion at a surgical site comprising application of such compositions. The compositions generally comprise a cellular adhesion inhibitory agent, such as dextran sulfate, and a crosslinked hydrogel matrix, preferentially physically entrapping the adhesion inhibitory agent. The hydrogel matrix can include a first gel component, such as an electrophilically functionalized polyethylene glycol polymer, and at least one additional gel component, preferably nucleophilically functionalized, and preferentially selected from the group consisting of polyethylene glycol polymers, polypeptides, and polysaccharides. The compositions are useful for delivering the cellular adhesion inhibitory agent to a site in need of adhesion inhibition and providing either immediate or metered delivery of the inhibitory agent.
Owner:TRIAD

Method for cell patterning

The present invention provides a masking system for selectively applying cells to predetermined regions of a surface. A mask is positioned adjacent to a surface to cover some portions of the surface while allowing other portions of the surface to remain uncovered. Cells then are applied to uncovered portions of the surface and the mask removed. Alternatively, a cell-adhesion promoter is applied to uncovered portions of the surface, and then cells are applied to the surface before or after removal of the mask from the surface. The masking system can be pre-coated, at least on those surfaces which will come into contact with cells, with a cell-adhesion inhibitor to resist absorption of cells and thereby avoid cell damage when the mask is removed (if cells are deposited prior to removal of the mask). A polymeric elastomeric mask that comes into cohesive-conformal contact with a surface to be patterned can be used.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Method for manufacturing cell culture substrate

A main object of the invention is to provide a new method for producing a cell culture substrate used to cause cells to adhere in a highly precise form onto a base material and then culture the cells. To attain the object, the invention provides a method for producing a cell culture substrate comprising: a patterning substrate forming process of forming, on a base material, a cell culture patterning layer wherein a cell adhesion portion having cell adhesive properties and a cell adhesion-inhibiting portion having cell adhesion-inhibiting properties can be formed by action of a photocatalyst by energy irradiation, thereby forming a patterning substrate; an energy irradiating process of irradiating the energy onto the cell culture patterning layer, thereby forming the cell adhesion portion and the cell adhesion-inhibiting portion in a pattern form by action of the photocatalyst; and a cell-containing liquid applying process of applying a cell-containing liquid onto the cell adhesion portion by a region-selecting applying method of applying the cell-containing liquid selectively onto the patterned cell adhesion portion.
Owner:DAI NIPPON PRINTING CO LTD

Formative agent of protein complex

The present invention proposes formative agent of protein complex, in which a polyphenol is useful component, and the agent is useful as gene complex, cell adhesion inhibitor or immune tolerogen. The polyphenol of forming the agent is selected from catechin group consisting of epigallocatechin-gallate, tannic acids, or proanto-dianisidine, a protein of the protein complex is selected from proteins consisting of animal proteins composed of polypeptide chain of peptide-combined amino acids, vegetative proteins, nucleus proteins, glycogen proteins, lipo-proteins and metal proteins, the gene complex comprises by compositing genes by polyphenol catechins in order to introduce genes to cells of animals or human bodies, a cell composed of the cell adhesion inhibitor is selected from cells consisting of an animal cell including a stem cell, skin cell, mucosa cell, hepatocyte, islet cell, neural cell, cartilage cell, endothelial cell, epidermal cell, osteocyte or muscle cell isolated from human or animal organism, or sperm, ovum or fertilized egg of domestic animals or fishes and a tissue or an organ for transplantation of the immune tolerogen is selected from the tissue or the organ consisting of skin, blood vessel, cornea, kidney, heart, liver, umbilical cord, bowels, nerve, lung, placenta or pancreas.
Owner:BERTELSMANN MUSIC GROUP

Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use

Disclosed is a method to recover an antigen presenting cells (APCs) and immune cells rich mixture (AIM) from peripheral blood mononuclear cells (PBMC) mobilized with one or more cell adhesion inhibitors for the preparation of an AIM vaccine or an AIM adoptive immunotherapy preparation. In addition, AIM mobilization can be enhanced by priming, simultaneously or in sequence, one or more of a combination of different chemical compounds, cytokines, hormones, growth factors, etc. The interaction of chemokines and chemokine receptors enable tumor cells attachment or in close proximity to antigen presenting cells and immune cells which possess similar receptors in a micro niche environment. Severing the chemokine / chemokine receptor linkage by a cell adhesion inhibitor will release these specifically primed cell mixtures into the peripheral blood. The collection of these cells from the peripheral blood has never been described and is the basis of this invention. AIM cells can either be used alone or better still, be induced into more target specific preparations with additions, modifications and incubation, pre or post cell adhesion inhibitors mobilization, with vaccines, different target specific antigens, peptides, chemotherapeutic agents, oncolytic viral therapeutic agents, cytokines, co-stimulatory molecules, anti-regulatory T cell therapeutic agents, anti-CTLA4, anti-PD1 molecules and other methodologies of immunological enhancement known to the art. The AIM vaccine or AIM adoptive immunotherapy preparation can then be used, but not limited to, the treatment of cancer and other diseases.
Owner:YEUNG ALEX WAH HIN +1

Medical device and method for producing the same

An object is to provide a medical device having excellent antithrombotic and sliding characteristics, which can exert a cell adhesion inhibitory effect. A medical device comprising: a substrate capable of forming hydroxyl groups; and a biocompatible material layer laminated on the substrate at an appropriate position, wherein the hydroxyl groups are formed on a surface of the substrate at least at a required position by a surface treatment, while the biocompatible material layer is formed from a polymer containing phosphorylcholine groups, and wherein the substrate and the biocompatible material layer are joined via a binder layer formed from silica being covalently bonded with the hydroxyl groups and the biocompatible material, respectively.
Owner:KYOCERA CORP +1

Pattering substrate and cell culture substrate

The present invention intends primarily to provide such as a cell culture patterning substrate that is used to adhere a cell in a highly precise pattern on a base material to culture and a cell culture substrate on which the cell is adhered in a high precision pattern. In order to achieve the above-mentioned object, the present invention provides a patterning substrate having a base material and a cell culture patterning layer that is formed on the base material and at least contains a photocatalyst and a cell adhesion-inhibiting material that has cell adhesion-inhibiting properties that inhibit the cell from adhering and is decomposed or modified owing to an action of the photocatalyst in combination with energy irradiation.
Owner:DAI NIPPON PRINTING CO LTD

Patterning substrate and cell culture substrate

The present invention intends primarily to provide such as a cell culture patterning substrate that is used to adhere cells in a highly precise pattern on a base material to culture and a cell culture substrate on which cells is adhered in a highly precise pattern. In order to attain the object, the invention provides a patterning substrate comprising a base material, a photocatalyst-containing layer which is formed on the base material and comprises at least a photocatalyst, and a cell adhesion-inhibiting layer which is formed on the photocatalyst-containing layer and comprises a cell adhesion-inhibiting material that has cell adhesion-inhibiting properties of inhibiting adhesion to cells and is decomposed or denatured by action of the photocatalyst on the basis of irradiation with energy.
Owner:DAI NIPPON PRINTING CO LTD

Patterning substrate and cell culture substrate

The present invention intends primarily to provide such as a cell culture patterning substrate that is used to adhere cells in a highly precise pattern on a base material to culture and a cell culture substrate on which cells are adhered in a highly precise pattern. To attain the object, the invention provides a patterning substrate comprising: a base material; and a cell adhesion-inhibiting layer which is formed on the base material and comprises a cell adhesion-inhibiting material that has cell adhesion-inhibiting properties of inhibiting adhesion to cells and is denatured by action of a photocatalyst on the basis of irradiation with energy.
Owner:DAI NIPPON PRINTING CO LTD

1,2-Di(cyclic)substituted benzene compounds

In one aspect, the present invention provides compounds having formula (1) or (100), a salt thereof or a hydrate of the foregoing, which compounds exhibit excellent cell adhesion inhibitory action or cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome; rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis. wherein R10 represents optionally substituted cycloalkyl, etc., R20-23 represent hydrogen, alkyl, alkoxy, etc., R30-32 represent hydrogen, alkyl, oxo, etc., and R40 represents optionally substituted alkyl, etc.
Owner:EISIA R&D MANAGEMENT CO LTD

Vascular cell culture patterning substrate

A vascular cell culture patterning substrate, which can efficiently form a plurality of blood vessels on one substrate. The vascular cell culture patterning substrate includes: a base material; a vascular cell adhesion portion formed in at least two substantially parallel lines on the base material, and having adhesive properties to a vascular cell which forms a blood vessel; and a vascular cell adhesion-inhibiting portion formed in between two adjacent vascular cell adhesion portions on the base material, and inhibiting adhesion to the vascular cell. The vascular cell adhesion-inhibiting portion contains a vascular cell adhesion-inhibiting material having vascular cell adhesion-inhibiting properties of inhibiting adhesion to the vascular cell.
Owner:DAI NIPPON PRINTING CO LTD

Formative agent of protein complex

The present invention proposes formative agent of protein complex, in which a polyphenol is useful component, and the agent is useful as gene complex, cell adhesion inhibitor or immune tolerogen. The polyphenol of forming the agent is selected from catechin group consisting of epigallocatechin-gallate, tannic acids, or proanto-dianisidine, a protein of the protein complex is selected from proteins consisting of animal proteins composed of polypeptide chain of peptide-combined amino acids, vegetative proteins, nucleus proteins, glycogen proteins, lipo-proteins and metal proteins, the gene complex comprises by compositing genes by polyphenol catechins in order to introduce genes to cells of animals or human bodies, a cell composed of the cell adhesion inhibitor is selected from cells consisting of an animal cell including a stem cell, skin cell, mucosa cell, hepatocyte, islet cell, neural cell, cartilage cell, endothelial cell, epidermal cell, osteocyte or muscle cell isolated from human or animal organism, or sperm, ovum or fertilized egg of domestic animals or fishes and a tissue or an organ for transplantation of the immune tolerogen is selected from the tissue or the organ consisting of skin, blood vessel, cornea, kidney, heart, liver, umbilical cord, bowels, nerve, lung, placenta or pancreas.
Owner:BERTELSMANN MUSIC GROUP

Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine

InactiveUS20080161566A1Excellent cell adhesion inhibitory actionOrganic active ingredientsNervous disorderUlcerative colitisAutoimmune disease
Salts and crystals of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine have excellent cell adhesion inhibitory action and cell infiltration inhibitory action, and are useful as therapeutic or prophylactic agents for various inflammatory diseases and autoimmune diseases associated with adhesion and infiltration of leukocytes, such as inflammatory bowel disease (particularly ulcerative colitis or Crohn's disease), irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, asthma and atopic dermatitis.
Owner:EISIA R&D MANAGEMENT CO LTD

Cell adhesion inhibitor

Provided is a cell adhesion inhibitor which exhibits low cytotoxicity and an excellent cell adhesion prevention effect; a tool and an apparatus each having a surface modified through application of the cell adhesion inhibitor thereto; a method for producing each of the surface-modified tool and apparatus; a biomedical structure and a production method therefor; and a microchannel device and a production method therefor.The invention provides a cell adhesion inhibitor comprising, as an active ingredient, a polymer comprising a repeating unit having a sulfinyl group in a side chain thereof.
Owner:JSR CORPORATIOON

Immunomodulator, cell adhesion inhibitor, and agent for treating, and preventing autoimmune diseases

Autoimmune diseases, cell adhesion inhibition and immunomodulation are treated or effected by a method, comprising, treating a patient with a therapeutically effective amount of a 4H-1-benzopyran-4-one compound represented by the following formula or a salt thereof: wherein R1 is an unsubstituted or halogen-substituted alkyl, alkenyl or aryl group; R2 is a hydrogen atom or an alkyl or acyl group; R3 is a hydrogen or halogen atom or a cyano, azido, carboxyl, hydroxyl, formyl or alkoxycarbonyl group or a substituted or unsubstituted alkyl, alkoxy, phenoxy, cycloalkyl, carbamoyl, amino or phenyl group; R4 is a hydrogen or halogen atom, a nitro, cyano, carboxyl, acyl, hydroxyl or alkoxycarbonyl group, or a substituted or unsubstituted alkyl, alkoxy, alkylthio, phenylthio, alkynyl, alkenyl, sulfamoyl, alkanesulfonyl, alkanesulfonyl, amidino, phenyl or heterocyclic group or a group of the formula where R6 is a hydrogen atom, a hydroxyl, cyano or alkoxycarbonyl group or a substituted or unsubstituted alkyl, cycloalkyl, phenyl, amino, acyl, carbamoyl, alkanesulfonyl, iminomethyl or amidino group and R7 is a hydrogen atom or a substituted or unsubstituted alkyl, alkoxy, phenyl, cycloalkyl or heterocyclic group, or R6 and R7, when taken together with the nitrogen atom to which the two are bonded, form a 3- to 7-membered, substituted or unsubstituted heterocyclic group; R5 is a substituted or unsubstituted phenyl, thienyl, furyl or pyridyl group; Z is an oxygen or sulfur atom or an imino group; and the broken line means a single or double bond.
Owner:TOYAMA CHEM CO LTD

1,2-di(cyclic) substituted benzene derivatives

InactiveUS20060281747A1Excellent cell adhesion inhibitory actionBiocideNervous disorderBenzeneMedicinal chemistry
A compound represented by the following general formula (1) or (100), a salt thereof or a hydrate of the foregoing has excellent cell adhesion inhibitory action and cell infiltration inhibitory action. wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH or nitrogen, and R20, R21, R22 and R23 may be the same or different and each represents hydrogen etc.
Owner:EISIA R&D MANAGEMENT CO LTD

Method For Preparing Extract From Wild Ginseng Showing Anticancer Activity And The Composition Comprising The Same

The present invention relates to a method for preparing purified extract from wild ginseng showing anticancer activity such as inhibitory of cancer cell adherence, inhibitory of cancer cell metastasis and immunostimulating effect and a composition comprising the same prepared by inventive method. The composition have potent anticancer activity, therefore, it can be used as the therapeutics for treating and preventing various cancer diseases.
Owner:SEOCKSANTEO MEDICAL

Cell pattern recovery tool

This invention provides a cell pattern recovery tool comprising a base material layer having a surface subjected to easy adhesion treatment, a temperature responsive polymer layer that is provided on the base material layer and has a surface subjected to silane treatment, and a cell adhesion inhibiting material layer provided on the temperature responsive polymer layer. According to the present invention, a cell pattern can be rapidly recovered while maintaining the cell pattern stably and reliably under minimally invasive conditions for the cells.
Owner:TOKYO WOMENS MEDICAL UNIV +1

Cell growth apparatus and use of aerogels for directed cell growth

This invention describes a cell growth apparatus, particularly neuronal printed circuit board apparatus comprising an aerogel base and a pre-printed cellular growth pattern. The cellular growth pattern is comprised of combinations of layers of cellular adhesion promoting materials, cellular adhesion inhibiting materials, and / or cellular signal promoting materials. The invention further describes methods of promoting cell growth using the neuronal printed circuit board apparatus of the invention. The invention is useful for regeneration and precise guidance of cells, particularly nerve cells, when used as an implant.
Owner:UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION

Polymer and crosslinked body thereof

Provided are a copolymer having enough biocompatibility to be used in a medical material application, and a method of forming a crosslinked body, which involves modifying a substrate surface with the copolymer so that the surface may be biocompatible. More specifically, a protein adsorption-suppressing effect and a cell adhesion-suppressing effect, which are features of a phosphorylcholine group, are imparted to the substrate surface. It has been found that the object is achieved by a copolymer containing a phosphorylcholine constitutional unit, a hydrophobic constitutional unit, and a photoreactive constitutional unit at a specific ratio.
Owner:THE UNIV OF TOKYO +1

Polymer composition, article, medical device, article production method, and cell cluster production method

The present invention relates to: a polymer composition; an article; a medical device; an article production method; and a cell cluster production method. The polymer composition contains a polymer having the following repeating units (A) and (B) and is one selected from the group consisting of a medical device composition, a cell adhesion inhibitor, and a silicone substrate treatment composition:(A) a hydrophilic repeating unit; and(B) a repeating unit which has a polyoxyalkylene group in a side chain whose terminal is constituted by an alkyl group having 5 to 30 carbon atoms, an alkanoyl group having 5 to 30 carbon atoms, or an aryl group having 6 to 30 carbon atoms.
Owner:JSR CORPORATIOON +1

Medical device and method for producing the same

An object is to provide a medical device having excellent antithrombotic and sliding characteristics, which can exert a cell adhesion inhibitory effect. A medical device comprising: a substrate capable of forming hydroxyl groups; and a biocompatible material layer laminated on the substrate at an appropriate position, wherein the hydroxyl groups are formed on a surface of the substrate at least at a required position by a surface treatment, while the biocompatible material layer is formed from a polymer containing phosphorylcholine groups, and wherein the substrate and the biocompatible material layer are joined via a binder layer formed from silica being covalently bonded with the hydroxyl groups and the biocompatible material, respectively.
Owner:KYOCERA CORP +1

Cell adhesion inhibitor (CAI) with combination growth factors mobilization of peripheral blood mononuclear cells for CAI derived dendritic cell (CdDC) preparation and dendritic cell vaccine preparations generated from CdDC

InactiveUS20110250687A1Successful immunotherapeutic responseIncrease opportunitiesVaccinesCancer antigen ingredientsCXCR4 antagonistChemical compound
Disclosed is a method to recover a dendritic cell rich mixture from peripheral blood mononuclear cells (PBMC) mobilized with one or more cell adhesion inhibitors (CAI) for the preparation of a dendritic cell vaccine. The CAI derived dendritic cell rich mixture (CdDC) from PBMC can either be used alone or better still, be induced into dendritic vaccine specific preparations with the addition or modification with different antigens and methodologies of immunological induction methods known to the art. These CAI derived dendritic vaccines can then be used, but not exclusively so, in the treatment of cancer and infectious diseases. In order to achieve the best immature and mature dendritic cell rich mixture, peripheral blood cells mobilization may be achieved by administering, simultaneously or in sequence, to an individual one or more of a combination of different chemical compounds, hormones, growth factors etc. prior to PBMC collection with one or more of cell adhesion inhibitors such as a CXCR4 antagonist.
Owner:YEUNG ALEX WAH HIN +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products